Viewing Study NCT01777958


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2026-02-23 @ 9:00 PM
Study NCT ID: NCT01777958
Status: COMPLETED
Last Update Posted: 2020-12-14
First Post: 2013-01-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module